DGAP-News
Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 2.17 per share - Seite 2
"This past year, 2021, was the most successful year in Dermapharm's 30-year history. Everyone in our Group can be extremely proud of this achievement. Even in the face of difficult conditions, we are looking to remain on our growth trajectory in 2022. We have already proven in the past that we can do this," said Dr Hans-Georg Feldmeier, Chairman of the Board of Management of Dermapharm Holding SE.
Based on the course of Dermapharm's business to date in 2022, the Board of Management confirmed the outlook for the full year, which forecast an increase of 10–13% in consolidated revenue and of 3–7% in consolidated EBITDA.
Company profile
Dermapharm – Pharmaceutical Excellence "Made in Germany"
Dermapharm is a rapidly growing manufacturer of branded pharmaceuticals. Founded in 1991, the Company is based in Grünwald near Munich. The Company's integrated business model comprises in-house development, production and the distribution of brand-name products by a trained pharmaceutical sales force. In addition to its main location in Brehna near Leipzig, Dermapharm also operates other production, development and distribution locations in Europe (primarily in Germany) and the United States.
In the "Branded pharmaceuticals and other healthcare products" segment, Dermapharm has approximately 1,300 marketing authorisations with more than 380 active pharmaceutical ingredients. Dermapharm's portfolio of pharmaceuticals, medical devices and food supplements are tailored to selected therapeutic areas in which the Company is a market leader, especially in Germany.
In the "Herbal extracts" segment, Dermapharm can tap the expertise of the Spanish company Euromed S.A., a leading global manufacturer of herbal extracts and plant-based active ingredients for the pharmaceuticals, nutraceuticals, foodstuffs and cosmetics industries. At the beginning of 2022, the segment was expanded to include Germany-based C³ Group, which develops, manufactures and markets synthetic cannabinoids. C³ Group is the market leader for dronabinol in Germany and Austria.